Systemic Galectin-3 in Smokers with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis: The Impact of Exacerbations.
COPD
CRP
airflow limitation
exacerbation
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
Historique:
received:
22
09
2020
accepted:
21
12
2020
entrez:
1
3
2021
pubmed:
2
3
2021
medline:
29
6
2021
Statut:
epublish
Résumé
The carbohydrate-binding protein Galectin-3 is increased in several inflammatory diseases and has recently been forwarded as a systemic biomarker in chronic obstructive pulmonary disease (COPD). In this longitudinal study, we characterized the level of systemic Galectin-3 using blood from smokers with a history of COPD and chronic bronchitis (COPD-CB), during stable clinical conditions and exacerbations. The study population comprised 56 long-term smokers with COPD-CB, 10 long-term smokers without lung disease (LTS) and 10 clinically healthy never-smokers (HNS). Blood samples were analyzed for levels of Galectin-3, leukocyte populations and C-reactive protein (CRP). In addition, sputum samples from the COPD-CB group were analyzed for bacterial growth. When comparing stable clinical conditions and exacerbations in the COPD-CB group, we found that the level of Galectin-3, just like that of CRP, leukocytes and neutrophils, respectively, was increased during exacerbations. However, this exacerbation-associated increase of Galectin-3 was modest. During stable clinical conditions of COPD-CB, the level of Galectin-3 was not elevated in comparison with HNS or LTS. Nor did this level of Galectin-3 distinguish patients that remained in a clinically stable condition throughout the study to those that developed an exacerbation. In addition, neither during stable clinical conditions nor during exacerbations, did the presence of bacterial growth in sputum alter Galectin-3 levels. In contrast to Galectin-3, the level of CRP, leukocytes and neutrophils, respectively, were increased during clinical stable conditions in the COPD-CB group compared with the other groups and were further enhanced during exacerbations. Systemic Galectin-3 is increased in a reproducible but modest manner during exacerbations in smokers with COPD-CB. During stable clinical conditions, the level of systemic Galectin-3 does not distinguish patients that remain clinically stable from those that develop exacerbations. This makes it less likely that systemic Galectin-3 may become a clinically useful biomarker in the current setting.
Identifiants
pubmed: 33642857
doi: 10.2147/COPD.S283372
pii: 283372
pmc: PMC7903965
doi:
Substances chimiques
Galectin 3
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
367-377Informations de copyright
© 2021 Sundqvist et al.
Déclaration de conflit d'intérêts
The authors declare no financial or non-financial conflicts of interest for this work.
Références
Am J Respir Crit Care Med. 2001 Apr;163(5):1256-76
pubmed: 11316667
Glycoconj J. 2004;19(7-9):575-81
pubmed: 14758082
Respir Care. 2015 Dec;60(12):1729-42
pubmed: 26106205
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Am J Respir Crit Care Med. 2013 Feb 1;187(3):228-37
pubmed: 23204254
Eur Heart J. 2013 Sep;34(36):2795-803
pubmed: 23832490
Eur Respir Rev. 2017 Jan 31;26(143):
pubmed: 28143876
Int J Chron Obstruct Pulmon Dis. 2015 Jun 30;10:1253-63
pubmed: 26170654
N Engl J Med. 2019 Jul 11;381(2):111-120
pubmed: 31291514
J Cell Sci. 2018 May 1;131(9):
pubmed: 29717004
Med Sci Monit. 2017 Sep 26;23:4612-4618
pubmed: 28947730
Sci Rep. 2017 Oct 18;7(1):13451
pubmed: 29044160
World J Gastrointest Oncol. 2010 Apr 15;2(4):177-80
pubmed: 21160594
J Intern Med. 2012 Jul;272(1):55-64
pubmed: 22026577
Cell Microbiol. 2013 Jul;15(7):1127-42
pubmed: 23279221
Eur Respir Rev. 2013 Dec;22(130):454-75
pubmed: 24293462
Clin Cancer Res. 2000 Apr;6(4):1389-93
pubmed: 10778968
Int J Chron Obstruct Pulmon Dis. 2015 Mar 27;10:689-702
pubmed: 25848245
Respir Res. 2015 Feb 21;16:28
pubmed: 25849664
Int J Chron Obstruct Pulmon Dis. 2016 Dec 12;11:3079-3091
pubmed: 28003742
Clin Biochem. 2010 May;43(7-8):683-90
pubmed: 20153309
Clin Chim Acta. 2015 May 20;445:155-60
pubmed: 25850080
J Immunol. 1995 Apr 1;154(7):3479-87
pubmed: 7897228
Mediators Inflamm. 2013;2013:413735
pubmed: 23956502
Glycoconj J. 2004;19(7-9):543-9
pubmed: 14758078
Glycobiology. 2009 Jan;19(1):16-20
pubmed: 18849325
Glycobiology. 1994 Feb;4(1):5-12
pubmed: 8186550
Am J Respir Crit Care Med. 2016 Mar 15;193(6):607-13
pubmed: 26745765
Chest. 2011 Sep;140(3):626-633
pubmed: 21474571
J Immunol. 1996 May 15;156(10):3939-44
pubmed: 8621934
Front Immunol. 2018 Apr 13;9:754
pubmed: 29706967
Blood. 1998 May 1;91(9):3430-8
pubmed: 9558402
Int J Mol Sci. 2018 Jan 26;19(2):
pubmed: 29373564
Heart. 2016 Jul 15;102(14):1134-41
pubmed: 27084804
Am J Pathol. 1995 Oct;147(4):1016-28
pubmed: 7573347
J Gene Med. 2018 Jan;20(1):
pubmed: 29165854
Eur Respir J. 2007 May;29(5):914-22
pubmed: 17251233
Cancer Res. 1995 Aug 1;55(15):3267-71
pubmed: 7542167
Am J Respir Crit Care Med. 2007 Feb 1;175(3):250-5
pubmed: 17053205
Respir Med. 2009 Jun;103(6):919-26
pubmed: 19121927
Respir Med. 2018 May;138:21-31
pubmed: 29724389
Am J Respir Crit Care Med. 1998 Oct;158(4):1277-85
pubmed: 9769292
Ann Med. 2013 May;45(3):291-300
pubmed: 23110517
J Immunol. 2002 Feb 15;168(4):1813-22
pubmed: 11823514
Mediators Inflamm. 2017;2017:9247574
pubmed: 28607536
Ann Med. 2011 Feb;43(1):60-8
pubmed: 21189092
Exp Ther Med. 2014 Feb;7(2):443-446
pubmed: 24396422
PLoS One. 2013;8(2):e56147
pubmed: 23441163